VHH E
An anti-RBD (SARS-CoV-2 Spike) nanobody.
General information
VHH E is a nanobody specific for SARS-CoV-2 Spike RBD. It was identified using the phage display technique and originally produced by an immune cell of a llama immunized with SARS-CoV-2 Spike RBD and inactivated SARS-CoV-2 virus. It does not compete in RBD-binding with VHH U, V, or W and thus, VHH E combined with any of these other nanobodies has a synergistic neutralizing effect. Simultaneous targeting of VHH E and VHH U/V/W epitopes prevents viral escape in vitro. The VHH E nanobody induces or stabilizes Spike protein in a “3-up” conformation (Koenig et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
Spike protein ACE2 Cryo-EM Crystallization Biophysical assay In vitro Mechanism Antibody |
llama and alpaca immune cells (source); in vitro biophysical assay; cryo-EM; crystallization; Vero E6 cells; Caco-2 cells; HEK293T cells; hACE2-HEK293T cells; SARS-CoV-2 Spike Δ18 pseudovirus; SARS-CoV-2 isolate SARS-CoV-2/human/Germany/Heinsberg-01/2020 | 41.85 | In vitro, the nanobody bound SARS-CoV-2 Spike RBD and inhibited SARS-CoV-2 Spike pseudotyped virus and live virus infection with IC50s of 60 nM and 48 nM, respectively. |
Feb/12/2021 |
